 
    Natalia Jiménez
Grup de recerca
- Genòmica translacional i teràpies dirigides en tumors sòlids Assistant researcher (R2C)
Publicacions destacades
- 
                    Glutamine and cholesterol plasma levels and clinical outcomes of patients with metastatic castration-resistant prostate cancer treated with taxanesAutors:Referència: Cancers 2021.
- 
                    Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate CancerAutors:Referència: Frontiers In Oncology 2020.
- 
                    Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate CancerAutors:Referència: Cells 2020.
- 
                    The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancerAutors:Referència: International Journal Of Cancer 2019.
- 
                    TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate CancerAutors:Referència: European Urology 2016.
- 
                    Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer PatientsAutors:Referència: Clinical Genitourinary Cancer 2016.
- 
                    Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancerAutors:Referència: Oncotarget 2015.
- 
                    Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate CancerAutors:Referència: Molecular Cancer Therapeutics 2014.
Projectes destacats
- 
                Plasticidad celular y perfil inmune asociados al tratamiento en cáncer de próstata metastásicoFinançador: Instituto de Salud Carlos IIIDurada: 01/01/2019 - 31/12/2021
- 
                Caracterización molecular del cáncer de próstata en función de la expresión de TMPRSS2-ERG: implicaciones terapéuticasFinançador: Instituto de Salud Carlos IIIDurada: 01/01/2016 - 31/12/2018
